Australia markets open in 1 hour 48 minutes

eFFECTOR Therapeutics, Inc. (EFTR)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.0800+0.0300 (+1.46%)
At close: 04:00PM EDT
2.0000 -0.08 (-3.85%)
After hours: 04:15PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 9.74M
Enterprise value 11.91M
Trailing P/E 0.84
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)13.38
Enterprise value/revenue N/A
Enterprise value/EBITDA -0.36

Trading information

Stock price history

Beta (5Y monthly) 0.52
52-week change 3-84.02%
S&P500 52-week change 325.38%
52-week high 337.0000
52-week low 31.6000
50-day moving average 38.0863
200-day moving average 312.4265

Share statistics

Avg vol (3-month) 3393.83k
Avg vol (10-day) 3135.04k
Shares outstanding 54.7M
Implied shares outstanding 64.7M
Float 83.59M
% held by insiders 12.84%
% held by institutions 114.02%
Shares short (15 Apr 2024) 4244.03k
Short ratio (15 Apr 2024) 40.3
Short % of float (15 Apr 2024) 46.67%
Short % of shares outstanding (15 Apr 2024) 46.62%
Shares short (prior month 15 Mar 2024) 4318.07k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:25
Last split date 312 Jan 2024

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-85.26%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -33.73M
Net income avi to common (ttm)-35.81M
Diluted EPS (ttm)-16.3700
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)18.37M
Total cash per share (mrq)4.98
Total debt (mrq)20.55M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.77
Book value per share (mrq)-1.94

Cash flow statement

Operating cash flow (ttm)-29.55M
Levered free cash flow (ttm)-17.73M